Key result
Cardiac glycosides, specifically digoxin, confer clinical benefit in patients with moderate to severe congestive heart failure even when added to therapy with vasodilators and diuretics.
Why the study?
Does digoxin provide clinical benefit in patients with moderate to severe congestive heart failure?
Population
Patients with moderate to severe congestive heart failure
Design
Review
Authors
Loading...
Supports digoxin consideration in moderate-severe HF; leaves mortality effects open pending NIH trial.
Does digoxin provide clinical benefit in patients with moderate to severe congestive heart failure?
This review highlights that digoxin provides clinical benefit in moderate to severe heart failure, with its effect on mortality being the subject of an ongoing NIH trial.
Kelly et al. (1994) conducted a review in Congestive heart failure. Cardiac glycosides (digoxin) was evaluated. Cardiac glycosides, specifically digoxin, confer clinical benefit in patients with moderate to severe congestive heart failure even when added to therapy with vasodilators and diuretics.